Y José Manuel Carrascosa (J M Carrascosa, Jose Manuel Carrascosa-Carrillo, Jose Manuel Carrascosa, José M Carrascosa, Jose Manuel Carrascosa Carrillo, José-Manuel Carrascosa, Jose M Carrascosa, José Manuel Carrascosa, Jose-Manuel Carrascosa, José Manuel Carrascosa Carrillo)

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 39

Top Venues

The Journal of dermatological treatment

Journal of the European Academy of Dermatology and Venereology : JEADV

Photodermatology, photoimmunology & photomedicine

Dermatologic therapy

Hospital Universitari Germans Trias i Pujol

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Hospital Universitari Germans Trias i Pujol Jan 1o 1996

Spain

Staff, associated professor :: dermatology

Publications

Mónica Munera-Campos, Y José Manuel Carrascosa
Atopic Dermatitis: Fertility, Pregnancy, and Treatment Perspectives. American journal of clinical dermatology (2023)
Antonio Costanzo, Mar Llamas Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera-Díaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluis Puig, Y José Manuel Carrascosa
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Tiago Torres, Jordi Galván, Nigel Crutchley, Morten Praestegaard, Lars Iversen, Paolo Gisondi, Y José Manuel Carrascosa, Bruno Halioua, Anthony Bewley, Andreas Pinter
Calcipotriol and Betamethasone Dipropionate Cream Based on PAD Technology for the Treatment of Plaque Psoriasis: A Narrative Review. Dermatology and therapy (2023)
José Juan Pereyra-Rodriguez, J L Poveda, A Rivero, E Serra-Baldrich, J F Silvestre, José-Carlos Armario-Hita, M Á Calleja, Y José Manuel Carrascosa, Á Flórez, P Herranz, Marta Comellas, F J Ortiz de Frutos
Assessing the value of moderate-to-severe atopic dermatitis treatment using Multi-Criteria Decision Analysis (MCDA). Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Y José Manuel Carrascosa
Conventional therapy in psoriasis. Lost in translation? The British journal of dermatology (2023)
Juan José Lluch, Y José Manuel Carrascosa, Alicia González-Quesada, Raquel Rivera-Díaz, Antonio Sahuquillo-Torralba, Mar Llamas-Velasco, Francisco José Gómez-García, Enrique Herrera-Acosta, Pablo de la Cueva, Ofelia Baniandrés-Rodríguez, Jose Luis Lopez-Estebaranz, Isabel Belinchón, Marta Ferrán, Almudena Mateu, Lourdes Rodríguez, Josep Riera-Monroig, M Teresa Abalde-Pintos, Gregorio Carretero, Carmen García-Donoso, Conrad Pujol-Marco, Elena Del Alcázar, Cristina Santamaría-Domínguez, Jorge Alonso Suárez-Pérez, Lula María Nieto-Benito, Diana Patricia Ruiz-Genao, Laura Salgado-Boquete, Miguel Ángel Descalzo, Ignacio García-Doval
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry. The British journal of dermatology (2023)
Isabel Belinchon Romero, Almudena Mateu Puchades, Miguel Ribera Pibernat, Diana P Ruiz Genao, Pablo de la Cueva Dobao, Y José Manuel Carrascosa
Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review. Annals of medicine 55 (1) (2023)
Johannes Griss, Gudrun Ratzinger, Julia-Tatjana Maul, Wolfgang Weger, Diamant Thaçi, Y José Manuel Carrascosa, Constanze Jonak
No impact of disease duration on response to tildrakizumab treatment among patients with moderate-to-severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies. Skin health and disease 3 (5) (2023)
Carlos Pelayo Hernández Fernández, Leopoldo Borrego, Pedro Mercader Garcìa, Gimenez-Arnau Ana Maria, Javier Sánchez Pérez, Juan Francisco Silvestre Salvador, Ricardo Gonzalez-Perez, Tatiana Sanz-Sánchez, Araceli Sánchez Gilo, Gemma Melé-Ninot, Violeta Zaragoza Ninet, Francisco Javier Miquel Miquel, Y José Manuel Carrascosa, Susana Cordoba-Guijarro, Maria-Elena Gatica-Ortega, Inmaculada Ruiz-Gonzalez, Esther Serra Baldrich, Fátima Tous Romero, Mercedes Rodríguez Serna, Maria-Antonia Pastor-Nieto, Patricia Pérez Feal, Marcos Hervella-Garces, Marina de Vega Martínez, Ignacio García Doval
Sensitization to isothiazolinones in the Spanish Contact Dermatitis Registry (REIDAC): 2019-2021 epidemiological situation. Contact dermatitis (2022)
Maria Fabregat-Pratdepadua, Elena Del Alcázar-Viladomiu, Júlia Verdaguer-Faja, Ariadna Quer Pi-Sunyer, Y José Manuel Carrascosa
Vegetative lesions associated with inhaled cocaine use. Clinical and experimental dermatology 47 (8) (2022)
Fátima Tous Romero, Gimenez-Arnau Ana Maria, Tatiana Sanz-Sánchez, Ricardo González Pérez, Y José Manuel Carrascosa, Violeta Zaragoza-Ninet, Susana Córdoba-Guijarro, Maria-Elena Gatica-Ortega, Javier Miquel-Miquel, Leopoldo Borrego, Inmaculada Ruíz-González, Esther Serra-Baldrich, Juan Francisco Silvester-Salvador, Pedro Mercader-García, Javier Sánchez-Pérez, Mercedes Rodríguez-Serna, Maria-Antonia Pastor-Nieto, Marcos Hervella-García, Ignacio García Doval, Francisco Javier Ortiz-de Frutos
Allergic contact dermatitis to alkyl glucosides: Epidemiological situation in Spain. Journal of the European Academy of Dermatology and Venereology : JEADV (2022)
Vicenç Rocamora, Laura Crespi, Marta Ferran, Mar Llamas Velasco, Elena Del Alcázar-Viladomiu, Y José Manuel Carrascosa, Emma Beltran, Ana Urruticoechea-Arana, José Luis López Estebaranz, David Vidal, Josep Riera, Lourdes Rodríguez, Susana Armesto, Josep M Fernández, Gloria Aparicio, Silvia Pérez, Saray Porcar Saura, Encarna Montesinos, Fernando Gallardo
Guselkumab effectiveness and survival in patients with psoriasis and psoriatic arthritis: Multicenter analysis in daily clinical practice by the Spanish Psoriasis Group. Dermatologic therapy 35 (11) (2022)
Néboa Zozaya, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, Y José Manuel Carrascosa, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio J GarcíA Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de Los Ríos Luna, Lluis Puig, Sandra Ros, Álvaro HIdalgo-Vega
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert review of pharmacoeconomics & outcomes research 22 (6) (2022)
Maria Fabregat-Pratdepadua, Aram Boada, José Luis Manzano, Juan José Lluch-Galcerá, Júlia Verdaguer-Faja, Ariadna Quer Pi-Sunyer, Y José Manuel Carrascosa
Development of morphea during Nivolumab treatment. The Australasian journal of dermatology 63 (2) (2022)
Elena Del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, Marc Julià, Ricardo Ruiz-Villaverde, Lourdes Rodríguez Fernández-Freire, Jaime Notario, Mar Llamas-Velasco, Marta Ferran, Y José Manuel Carrascosa
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. The Journal of dermatological treatment 33 (6) (2022)
Ulrich Mrowietz, Peter Van De Kerkhof, Andreu Schoenenberger, Anna Ryzhkova, Ignasi Pau-Charles, Mar Llamas-Velasco, Esteban Daudén, Y José Manuel Carrascosa, Pablo De La Cueva, Laura Salgado-Boquete, Meritxell Guilà, Francisco Javier Fernández-Soriano, Matthias Augustin, Christine Loew-Juettner, Astrid Kirsch, Sebastian Diemert, Ina Hadshiew
Efficacy of dimethyl fumarate treatment for moderate-to-severe plaque psoriasis: presentation extracts from the 29th EADV virtual congress, 29-31 October 2020. Expert review of clinical immunology 17 (sup2) (2021)
Isabel Belinchón-Romero, Esteban Dauden, Carlos Ferrándiz Foraster, Álvaro González-Cantero, Y José Manuel Carrascosa, null null
PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines. The Journal of dermatological treatment (2021)
D Thaçi, Denis Jullien, Alexander Egeberg, Y José Manuel Carrascosa, J J Wu, I Pau-Charles, Paolo Gisondi
Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (11) (2021)
Elena Del Alcázar-Viladomiu, Anna López-Ferrer, Álvaro Martínez Domenech, Ricardo Ruíz-Villaverde, Mar Llamas Velasco, Vicenç Rocamora, Marc Julià, Jaime Notario, Lourdes Rodríguez Fernández-Freire, Antonio Sahuquillo-Torralba, David Vidal, Raquel Rivera-Díaz, Gregorio Carretero, Almudena Mateu, Pablo de la Cueva, Y José Manuel Carrascosa
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic therapy (2021)
Amelia Melo, Y José Manuel Carrascosa, Tiago Torres
Baricitinib for the treatment of atopic dermatitis. The Journal of dermatological treatment (2021)
M Munera-Campos, J Vilar-Alejo, R Rivera, Y José Manuel Carrascosa, E Daudén, E Herrera-Acosta, A Sahuquillo-Torralba, F J Gómez-García, O Baniandrés-Rodríguez, P de la Cueva, J L López-Estebaranz, I Belinchón, M Ferran, J Riera-Monroig, L Rodriguez, G Carretero, C García-Donoso, F Ballescá, M Llamas-Velasco, E Herrera-Ceballos, C Pujol-Marco, Lula María Nieto-Benito, D P Ruiz-Genao, M Alsina, M A Descalzo, I García-Doval, null null
The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry. The Journal of dermatological treatment (2021)
G Carretero, Y José Manuel Carrascosa, Lluis Puig, J L Sánchez-Carazo, A López-Ferrer, P Cueva, C Soria, Raquel Rivera-Díaz, Isabel Belinchón-Romero, null null
Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Deepak M W Balak, Y José Manuel Carrascosa, Stamatis Gregoriou, Piergiacomo Calzavara-Pinton, Anthony Bewley, Joana Antunes, Martin E Nyeland, Marta G Viola, Laura M Sawyer, Lidia Becla
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countries. The Journal of dermatological treatment 32 (7) (2020)
R B Warren, Y José Manuel Carrascosa, E Fumero, A Schoenenberger, M G Lebwohl, Jacek Cezary Szepietowski, Kristian Reich
Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (4) (2020)
Alexander Egeberg, Paolo Gisondi, Y José Manuel Carrascosa, R B Warren, Ulrich Mrowietz
The role of the interleukin-23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)
Fernando de Mora, Alejandro Balsa, María Cornide-Santos, Y José Manuel Carrascosa, Sara Marsal, Francisco Javier García-Alonso, Miguel-Angel Abad, Rafael F Duarte, Michael Wiechmann, Rafael Martínez
Biosimilar and interchangeable: Inseparable scientific concepts? British journal of clinical pharmacology 85 (11) (2019)
Elena Del Alcázar, Marta Ferran, Anna López-Ferrer, Jaime Notario, David Vidal, José Riera, Gloria Aparicio, Fernando Gallardo, Eva Vilarrasa, Mercè Alsina, Lluis Puig, Carlos Ferrándiz, Y José Manuel Carrascosa
Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. The Journal of dermatological treatment 31 (3) (2019)
Lluis Puig, Y José Manuel Carrascosa, Esteban Daudén, Sara Sulleiro, Cristina Guisado
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. The Journal of dermatological treatment 31 (4) (2019)
Y José Manuel Carrascosa, E Del-Alcazar
New therapies versus first-generation biologic drugs in psoriasis: a review of adverse events and their management. Expert review of clinical immunology 14 (4) (2018)
M Toro-Montecinos, F Ballescá, C Ferrandiz, A Teniente-Serra, E Martinez-Caceres, Y José Manuel Carrascosa
Usefulness and correlation with clinical response of serum ustekinumab levels measured at 6 weeks versus 12 weeks. The Journal of dermatological treatment 30 (1) (2018)
Y José Manuel Carrascosa, Francisco Rebollo, Susana Gómez, Plablo De-la-Cueva
Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. The Journal of dermatological treatment 29 (8) (2018)
Néboa Zozaya, Lucía Martínez-Galdeano, Bleric Alcalá, Jose Carlos Armario-Hita, Concepción Carmona, Y José Manuel Carrascosa, Pedro Herranz, María Jesús Lamas, Marta Trapero-Bertran, Álvaro Hidalgo-Vega
Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 32 (3) (2018)
Mónica Munera-Campos, Gonzalo Castillo, Carlos Ferrándiz, Y José Manuel Carrascosa
Actinic lichen planus triggered by drug photosensitivity. Photodermatology, photoimmunology & photomedicine 35 (2) (2018)
Andrea Montes-Torres, Gloria Aparicio, Raquel Rivera, Eva Vilarrasa, María Marcellán, Jaume Notario, Caridad Soria, Isabel Belinchón, Pablo de la Cueva, Marta Ferrán, Y José Manuel Carrascosa, Francisco J Gómez, Laura Salgado, Manuel Velasco, Miguel Ángel Descalzo, Ignacio García Doval, Esteban Daudén, null null
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study. The Journal of dermatological treatment 30 (5) (2018)
Jaime Notario, Gustavo Deza, Eva Vilarrasa, Francesc Valentí, Carlos Muñoz, Jordi Mollet, Vicenç Rocamora, Y José Manuel Carrascosa, Elena Del Alcázar, Mercè Alsina, David Vidal, Lluis Puig, Anna López-Ferrer, José Riera, Fernando Gallardo, Marta Ferran
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. The Journal of dermatological treatment 30 (5) (2018)
Y José Manuel Carrascosa, M Toro Montecinos, F Ballescá, A Teniente Serra, E Martínez Cáceres, C Ferrándiz
Correlation between trough serum levels of adalimumab and absolute PASI score in a series of patients with psoriasis. The Journal of dermatological treatment 29 (2) (2017)
Denise Gamé, Juli Bassas, Cristina Grau, Carlos Ferrándiz, Y José Manuel Carrascosa
Fixed sunlight eruption: a new idiopathic photodermatosis rather than a variant of fixed drug eruption. Photodermatology, photoimmunology & photomedicine 33 (4) (2017)
Y José Manuel Carrascosa, Nuria Floriach, Elisabet Sala, Jose Aguilera
Increase in minimal erythemal dose following oral administration of an antioxidant complex based on a mix of carotenoids: Double-blind, placebo-controlled trial. Photodermatology, photoimmunology & photomedicine 33 (5) (2017)
G Carretero, Lluis Puig, Y José Manuel Carrascosa, L Ferrándiz, R Ruiz-Villaverde, P de la Cueva, I Belinchon, E Vilarrasa, R Del Rio, J L Sánchez-Carazo, A López-Ferrer, F Peral, S Armesto, N Eiris, J Mitxelena, J Vilar-Alejo, M A Martin, C Soria, null null
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. The Journal of dermatological treatment 29 (4) (2017)

Publication Activity (10 Years)

Top Topics

Top Venues